Mazen Noureddin, MD, MHSc (@noureddinmd) 's Twitter Profile
Mazen Noureddin, MD, MHSc

@noureddinmd

Prof of Med, Hepatologist @Methodisthosp. Researcher, Dir Houston Research Institute. Father to 2 girls. AE @AGA_CGH

ID: 801899674001031168

calendar_today24-11-2016 21:25:55

2,2K Tweet

5,5K Followers

1,1K Following

Mazen Noureddin, MD, MHSc (@noureddinmd) 's Twitter Profile Photo

What a day in the history of MASH! Reversal of Fibrosis in MASH cirrhotics by 24% (paired) and 17% (ITT) all sig P values. Same for NITs!!!! Happy for the our patients. FGF21s are here to stay!! #livertwitter Elliot Tapper Naim Alkhouri akerotx globenewswire.com/news-release/2…

AASLD (@aasldtweets) 's Twitter Profile Photo

📅 Happening this month! Don’t miss this unparalleled opportunity to dive deep into the most pressing challenges and innovations in #MASLD, #MetALD and #ALD. View the program and register now! #LiverTwitter Juan Pablo (JP) Arab, MD  Mazen Noureddin, MD, MHSc bit.ly/4gq0PNN

📅 Happening this month!

Don’t miss this unparalleled opportunity to dive deep into the most pressing challenges and innovations in #MASLD, #MetALD and #ALD.

View the program and register now! #LiverTwitter <a href="/juanpabloarab/">Juan Pablo (JP) Arab, MD </a> <a href="/NoureddinMD/">Mazen Noureddin, MD, MHSc</a>

bit.ly/4gq0PNN
Mónica Tincopa MD MSc (@monicatincopa) 's Twitter Profile Photo

Happening now in SDCC 32 Digestive Disease Week #Obesity and Advanced #LiverDisease With Mazen Noureddin, MD, MHSc moderating Juan Pablo (JP) Arab, MD  discussing #ETOH and obesity Puneet Puri discussing #AOM & #MASH I will discuss the role of treatments that don’t also impact obesity in MASH 🤔

Happening now in SDCC 32 <a href="/DDWMeeting/">Digestive Disease Week</a> 
#Obesity and Advanced #LiverDisease

With <a href="/NoureddinMD/">Mazen Noureddin, MD, MHSc</a> moderating 
<a href="/juanpabloarab/">Juan Pablo (JP) Arab, MD </a> discussing #ETOH and obesity
<a href="/PuneetPuri18/">Puneet Puri</a> discussing #AOM &amp; #MASH
I will discuss the role of treatments that don’t also impact obesity in MASH 🤔
Mazen Noureddin, MD, MHSc (@noureddinmd) 's Twitter Profile Photo

Great topline data by Neuraly Inc. DD01 (Dual GLP-1/Glucagon) in MASH patients! More option for our patients on the way!! Thanks to the patients, investigators and Summit Clinical Research Pinnacle Clinical Research for making this possible #livertwitter businesswire.com/news/home/2025…

Ramon Bataller (@rabataller) 's Twitter Profile Photo

Today, NEJM reports that Efruxifermin (an FGF21 agonist) is the first drug to reduce fibrosis in compensated cirrhosis due to NASH. This effect is seen after 96 weeks, so patience is key. Could combining Semaglutide make it even more powerful?

Today, <a href="/NEJM/">NEJM</a> reports that Efruxifermin (an FGF21 agonist) is the first drug to reduce fibrosis in compensated cirrhosis due to NASH. 

This effect is seen after 96 weeks, so patience is key. 

Could combining Semaglutide make it even more powerful?